Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 400

1.

Novel secondary hormonal therapy in advanced prostate cancer: an update.

Van Allen EM, Ryan CJ.

Curr Opin Urol. 2009 May;19(3):315-21. doi: 10.1097/MOU.0b013e328329b73a. Review.

PMID:
19342958
2.

Secondary hormonal manipulations in prostate cancer.

Ryan CJ, Small EJ.

Curr Oncol Rep. 2005 May;7(3):228-33. Review.

PMID:
15847715
3.

Novel concepts in androgen receptor blockade.

Hsieh AC, Ryan CJ.

Cancer J. 2008 Jan-Feb;14(1):11-4. doi: 10.1097/PPO.0b013e318161d13e. Review.

PMID:
18303477
4.

The case for secondary hormonal therapies in the chemotherapy age.

Small EJ, Ryan CJ.

J Urol. 2006 Dec;176(6 Pt 2):S66-71. Review.

PMID:
17084172
5.

Secondary hormonal therapy for advanced prostate cancer.

Lam JS, Leppert JT, Vemulapalli SN, Shvarts O, Belldegrun AS.

J Urol. 2006 Jan;175(1):27-34. Review.

PMID:
16406864
6.

[Androgen-deprivation therapy in prostate cancer: clinical evidence and future perspectives].

Pinto F, Calarco A, Totaro A, Sacco E, Volpe A, Racioppi M, D'Addessi A, Bassi PF.

Urologia. 2010 Apr-May;77(2):71-83. Review. Italian.

PMID:
20890863
7.

Innovative approaches to the hormonal treatment of advanced prostate cancer.

Trachtenberg J.

Eur Urol. 1997;32 Suppl 3:78-80. Review.

PMID:
9267790
8.

Secondary hormonal manipulations in prostate cancer.

Ryan CJ.

Hematol Oncol Clin North Am. 2006 Aug;20(4):925-34. Review.

PMID:
16861123
9.

Androgen receptor: role and novel therapeutic prospects in prostate cancer.

Taplin ME.

Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. doi: 10.1586/14737140.8.9.1495. Review.

PMID:
18759700
10.

Hormonal therapy for prostate cancer: toward further unraveling of androgen receptor function.

Sharifi N.

Anticancer Agents Med Chem. 2009 Dec;9(10):1046-51. Review.

PMID:
19719456
11.

Recent progress in hormonal therapy for advanced prostate cancer.

Daskivich TJ, Oh WK.

Curr Opin Urol. 2006 May;16(3):173-8. Review.

PMID:
16679855
12.

Mechanisms leading to the development of hormone-resistant prostate cancer.

Kasper S, Cookson MS.

Urol Clin North Am. 2006 May;33(2):201-10, vii. Review.

PMID:
16631458
13.

Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.

Suzuki H, Okihara K, Miyake H, Fujisawa M, Miyoshi S, Matsumoto T, Fujii M, Takihana Y, Usui T, Matsuda T, Ozono S, Kumon H, Ichikawa T, Miki T; Nonsteroidal Antiandrogen Sequential Alternation for Prostate Cancer Study Group.

J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.

PMID:
18635218
14.

Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer.

Nishiyama T, Suzuki K, Yamana K, Tonegawa E, Wako K, Takahashi K.

Expert Rev Anticancer Ther. 2006 Feb;6(2):259-68. Review.

PMID:
16445378
15.

Secondary hormonal therapies in the treatment of prostate cancer.

OH WK.

Urology. 2002 Sep;60(3 Suppl 1):87-92; discussion 93. Review.

PMID:
12231058
16.

Drug insight: role of the androgen receptor in the development and progression of prostate cancer.

Taplin ME.

Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. Review.

PMID:
17392714
17.

Secondary hormonal manipulation of prostate cancer.

Harris KA, Small EJ.

Curr Urol Rep. 2001 Jun;2(3):224-30. Review.

PMID:
12084269
18.

Molecular determinants of resistance to antiandrogen therapy.

Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL.

Nat Med. 2004 Jan;10(1):33-9. Epub 2003 Dec 21.

PMID:
14702632
19.

Androgen receptor gene amplification: a novel molecular mechanism for endocrine therapy resistance in human prostate cancer.

Koivisto P, Visakorpi T, Kallioniemi OP.

Scand J Clin Lab Invest Suppl. 1996;226:57-63. Review.

PMID:
8981668
20.

Recent advances in understanding hormonal therapy resistant prostate cancer.

Donkena KV, Yuan H, Young CY.

Curr Cancer Drug Targets. 2010 Jun;10(4):402-10. Review.

PMID:
20464780

Supplemental Content

Support Center